Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: Comparison of the effects of 17-β oestradiol and raloxifene

Journal of Endocrinology

Volumn 177, Issue 3, 2003, Pages 423-433

  Cheung, J ^c   Mak, Y T ^c   Papaioannou, S ^a   Evans, B A J ^b   Fogelman, I ^a   Hampson, Geeta ^c  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BONE MARROW CELL; CELL IMMORTALIZATION; CELL LINEAGE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOLYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; STEADY STATE; STROMA CELL;

CARRIER PROTEINS; CELL LINE; CELL LINE, TRANSFORMED; CYTOKINES; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; GLYCOPROTEINS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; OSTEOBLASTS; OSTEOPROTEGERIN; RALOXIFENE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0038377650     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1770423     Document Type: Article

References (36)

1. Bradford M 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
2. Brändström H, Jonsson KB, Vidal O, Lunghal, Ohlsson C & Ljunggren O 1998 Tumour necrosis factor-α and β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochemical and Biophysical Research Communications 248 454-457.
3. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
4. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J & Pacifici R 2000 Estrogen deficiency induces bone loss by enhancing T-cell production of TNF- α. Journal of Clinical Investigation 106 1229-1237.
5. Cheng S, Yang JW, Rifas L, Zhang S & Avioli LV 1994 Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology 134 277-286.
6. Compston JE 2001 Sex steroids and bone. Physiological Reviews 81 419-447.
7. Davies JH, Evans BAJ, Jenney MEM & Gregory JW 2002 In vitro effects of chemotherapeutic agents on human osteoblast-like cells. Calcified Tissue International 70 408-415.
8. Etinger B, Black DM, Mittak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P & Cummings SR 1999 Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. Journal of the American Medical Association 282 637-645.
9. Harrison AJ 1996 Evidence of multipotency in immortalised cells derived from bone marrow stroma. PhD Thesis. University of Manchester.
10. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL & Khosla S 1998 Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2 and cytokines. Biochemical and Biophysical Research Communications 250 776-781.
11. Hofbauer LC, Khosla S, Dunstand CR, Lacey DL, Spelsberg TC & Riggs BL 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 4367-4370.
12. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 15 2-12.
13. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliot R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB & Boyle WJ 1999 Tumour necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. PNAS 96 3540-3545.
14. Hughes DE, Dai A, Tiffee JC, Li HH & Mundy GR 1997 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nature Medicine 2 1132-1136.
15. Kassem M, Harris SA, Spelsberg TC & Riggs BL 1996 Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors. Journal of Bone and Mineral Research 11 193-199.
16. Khosla S, Atkinson EJ, Dunstan CR & O'Fallon WM 2002 Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology 87 1550-1554.
17. Lindberg MK, Erlandsson M, Alatalo SL, Windahl S, Andersson G, Halleen JM, Carlsten H, Gustafsson J-A & Ohlsson C 2001 Estrogen receptor α, but not estrogen receptor β, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-κB ligand) ratio and serum interleukin-6 in male mice. Journal of Endocrinology 171 425-433.
18. Lonard DM & Smith CL 2002 Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67 15-24.
19. Morishita M, Shimazu A & Iwamoto Y 1999 Analysis of oestrogen receptor in mRNA by reverse transcriptase polymerase chain reaction in human periodontal ligament cells. Archives of Oral Biology 44 781-783.
20. Ogston N, Harrison AJ, Cheung HFJ, Ashton BA & Hampson G 2002 Dexamethasone and retinoic acid differentially regulate growth and differentiation in an immortalised human clonal bone marrow stromal cell line with osteoblastic characteristics. Steroids 67 895-906.
21. Oursler MJ 1998 Estrogen regulation of gene expression in osteoblasts and osteoclasts. Critical Reviews in Eukaryotic Gene Expression 8 125-140.
22. Oursler MJ, Cortese C, Keeting PE, Anderson MA, Bonde SK, Riggs BL & Spelsberg TC 1991 Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology 129 3313-3320.
23. Pacifi R 1998 Cytokines, estrogen and post-menopausal osteoporosis. The second decade. Endocrinology 139 2659-2661.
24. Poola I, Abraham J & Baldwin K 2002 Identification of ten exon deleted ERβ mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor α. FEBS Letters 516 133-138.
25. Riggs BL, Khosla S & Melton LJ 2002 Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 23 279-302.
26. Saika M, Inoue D, Kido S & Matsumoto T 2001 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 142 2205-2212.
27. Shang Y & Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295 2465-2468.
28. Sherde NK, Bendixen AC, Dienger KM & Pike JW 2000 Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving C-Jun repression. PNAS 97 7829-7834.
29. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
30. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, De Rose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sanders S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program & Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 309-319.
31. Spelsberg TC, Subramaniam M, Riggs BL & Khosla S 1999 The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Molecular Endocrinology 13 819-828.
32. Taranta A, Brama M, Teti A, De Luca V, Seandurra R, Spera G, Agnusdei D, Termine JD & Migliaccio S 2002 The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 368-376.
33. Vidal NO, Bränström H, Jonsson KB & Ohlsson C 1998a Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. Journal of Endocrinology 159 191-195.
34. Vidal ON, Sjögren K, Eriksson BI, Ljunggren O & Ohlsson C 1998b Osteoprotegerin mRNA is increased by interleukin-α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochemical and Biophysical Research Communications 248 696-700.
35. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K & Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in post-menopausal women with osteoporosis. Journal of Bone and Mineral Research 14 518-527.
36. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi W & Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANK L. PNAS 95 3597-3602.